NASDAQ
IMGN

ImmunoGen Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

ImmunoGen Inc Stock Price

Vitals

Today's Low:
$5.4100
Today's High:
$5.7200
Open Price:
$5.5900
52W Low:
$3.1
52W High:
$7.77
Prev. Close:
$5.6200
Volume:
3315568

Company Statistics

Market Cap.:
$1.214 billion
Book Value:
1.132
Revenue TTM:
$0.089 billion
Operating Margin TTM:
-170.7%
Gross Profit TTM:
$-0.081 billion
Gross Profit TTM:
$-0.081 billion
Profit Margin:
-179.6%
Return on Assets TTM:
-26.4%
Return on Equity TTM:
-101%

Company Profile

ImmunoGen Inc had its IPO on 1990-03-26 under the ticker symbol IMGN.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. ImmunoGen Inc has a staff strength of 0 employees.

Stock update

Shares of ImmunoGen Inc opened at $5.59 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $5.41 - $5.72, and closed at $5.5.

This is a -2.14% slip from the previous day's closing price.

A total volume of 3,315,568 shares were traded at the close of the day’s session.

In the last one week, shares of ImmunoGen Inc have slipped by -8.33%.

ImmunoGen Inc's Key Ratios

ImmunoGen Inc has a market cap of $1.214 billion, indicating a price to book ratio of 5.35 and a price to sales ratio of 13.57.

In the last 12-months ImmunoGen Inc’s revenue was $0.089 billion with a gross profit of $-0.081 billion and an EBITDA of $-0.151 billion. The EBITDA ratio measures ImmunoGen Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ImmunoGen Inc’s operating margin was -170.7% while its return on assets stood at -26.4% with a return of equity of -101%.

In Q2, ImmunoGen Inc’s quarterly earnings growth was a positive 407.8% while revenue growth was a negative 16.4%.

ImmunoGen Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
0

Its diluted EPS in the last 12-months stands at $-0.589 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ImmunoGen Inc’s profitability.

ImmunoGen Inc stock is trading at a EV to sales ratio of 10.97 and a EV to EBITDA ratio of -6.47. Its price to sales ratio in the trailing 12-months stood at 13.57.

ImmunoGen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

ImmunoGen Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

ImmunoGen Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

ImmunoGen Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, ImmunoGen Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, ImmunoGen Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$5.5
52-Week High
$7.77
52-Week Low
$3.1
Analyst Target Price
$11.21

ImmunoGen Inc stock is currently trading at $5.5 per share. It touched a 52-week high of $7.77 and a 52-week low of $7.77. Analysts tracking the stock have a 12-month average target price of $11.21.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About ImmunoGen Inc

The stock symbol (also called stock or share ticker) of ImmunoGen Inc is IMGN

The IPO of ImmunoGen Inc took place on 1990-03-26

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$7.44
-0.32
-4.12%
$4.13
-0.29
-6.56%
Xencor Inc (XNCR)
$27.43
-0.84
-2.97%
$16.64
-0.19
-1.13%
$22.89
-0.24
-1.04%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company is headquartered in Waltham, Massachusetts.

Address

830 WINTER ST, WALTHAM, MA, US